|Composition||Canine leptospirosis vaccine|
|Treatment||immunization against leptospirosis in dogs|
|Packaging Size||1 vail|
Nobivac Lepto 1 contains inactivated Leptospira Icterohaemorrhagiae to provide protection against canine Leptospirosis caused by Leptospira Copenhagenii. Nobivac Lepto 1 is a liquid vaccine that can be used for reconstitution of freeze-dried Nobivac canine vaccines.
The Nobivac L4 lepto vaccine, which was rolled out in the UK by Merck's UK subsidiary, MSD Animal Health, is reportedly causing adverse effects in the dogs receiving it, including epilepsy, swollen glands, blindness and death.
|Packaging Size||1 vail|
|Composition||combined rabies & canine leptospirosis vaccine,inactivated|
|Treatment||for active immunisation of dog agaist rabies and canine leptospirosis|
Vaccine for dogs against Rabies and canine leptospirosis caused by L. interrogans serotype canicola and icterohaemorrhagiae.
Systemic reactions include fever, depression, loss of appetite, lethargy and weakness. They usually appear within 1-2 days of vaccination and then disappear. Nervous system problems have been seen after vaccination with modified live rabies (no longer available) and canine distemper vaccines.
|Packaging Size||10 X1|
A live attenuated freeze-dried vaccine containing canine distemper virus, canine adenovirus (CAV-2), canine parvovirus (C154) and canine parainfluenza virus.
Active immunisation of healthy dogs against canine distemper virus, canine adenovirus type 1 (infectious canine hepatitis), canine parvovirus and against canine cough caused by canine adenovirus type 2 and canine parainfluenza virus.
Reconstitute each single dose vial of the vaccine with one vial of Nobivac diluent or Nobivac Lepto I and administer by subcutaneous injection.
Each of the Nobivac vaccines fits into a larger overall vaccination programme. The individual’s age, health (including maternal immunity) and local environmental conditions should be considered in the formulation of a vaccination programme.
|Packaging Size||1 vail|
|Composition||rabies vaccine ,inactivated|
|Shelf life||21 month|
For the active immunization of healthy dogs, cats, cattle, sheep, goats, horses, ferrets, foxes and in principle all healthy mammals against rabies. It can be used for both prophylactic immunization & post bite therapy. 1ml by subcutaneous or intramuscular injection.
SIDE EFFECTS :
injection site reactions (pain, swelling, itching, or redness),
|Minimum Order Quantity||1 per vial|
|Packaging Size||1 Vial|
|Composition||cell cultured, inactivated vaccine|
|Treatment||vaccinated against rabies|
Nobivac ® 1-Rabies vaccine is for vaccination of healthy dogs, cats and ferrets as an aid in preventing rabies. The vaccine is prepared from cell-culture-grown, chemically-inactivated rabies virus. ... The inactivated virus is formulated with a highly purified adjuvant and is packaged in liquid form.
Swelling or firmness of the skin at the vaccination site.
Mild allergic reaction.
|Packaging Size||1 VAIL|
|Composition||inactivated rabiesv antigen|
Rabisin Vaccine for dogs & cats.
An inactivated vaccine against rabies, presented as a clear colourless suspension for injection.
Each 1ml dose contains at least 1IU rabies virus glycoproteins. Also contains aluminium hydroxide adjuvant.
For the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.Immunity has been demonstrated 1 month after vaccination and has been shown to persist up to the next re-vaccination dose.
Dosage and administration
Inject one 1 ml dose subcutaneously, according to the following schedule:
Minimum age at vaccination: 3 months.
Booster vaccination should be given every two years.
|Packaging Size||1 ml|
For active immunisation of dogs to prevent mortality and clinical signs caused by canine distemper virus infection. To reduce clinical signs of infectious hepatitis and viral excretion due to canine adenovirus type 1 infection. To prevent mortality, clinical signs and viral excretion following canine parvovirus infection. To reduce clinical signs and viral excretion caused by canine parainfluenza virus infection and to reduce clinical signs of respiratory disease and viral excretion following adenovirus type 2 infection.
An onset of immunity to the canine distemper virus, canine adenovirus and canine parvovirus vaccine components of 1 week and an onset of immunity of 4 weeks to the canine parainfluenza virus vaccine component has been demonstrated following use of the vaccine.
|Packaging Size||50 ml|
Rabies Vaccine, KILLED VIRUS
Provides protection against rabies in dogs, cats and ferrets for at least one year.
Features and Benefits
Proven to be uniformly safe in experimental tests
Administration and Dosage
Nobivac® Puppy DP. A live attenuated freeze-dried vaccine containing canine distemper virus and canine parvovirus (C154). Active immunisation of young puppies against canine distemper virus, and canine parvovirus infection. The puppy vaccination programme can be completed from a minimum of 10 weeks of age.
Loss of appetite.
Facial or paw swelling and/or hives.
Pain or swelling around the injection site.
Collapse, difficulty breathing, and seizures (anaphylactic shock)